NextPharma develops and registers its own generic dossiers which we then license to sell, market and distribute to partners across the world and as a leading CDMO, can ensure the supply for both product launch and commercial demand.
The following products have been approved in Europe through decentralized procedure:
- Elevin 20/100: Ethinylestradiol 20µg / Levonorgestrel 100µg
- Elevin 30/150: Ethinylestradiol 30µg / Levonorgestrel 150µg
- Diena: Ethinylestradiol 30µg / Dienogest 2000µg
- Desomono: Desogestrel 75µg